| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Fcmr |
| Uniprot No | O60667 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-390aa |
| 氨基酸序列 | MDFWLWPLYFLPVSGALRILPEVKVEGELGGSVTIKCPLPEMHVRIYLCREMAGSGTCGTVVSTTNFIKAEYKGRVTLKQYPRKNLFLVEVTQLTESDSGVYACGAGMNTDRGKTQKVTLNVHSEYEPSWEEQPMPETPKWFHLPYLFQMPAYASSSKFVTRVTTPAQRGKVPPVHHSSPTTQITHRPRVSRASSVAGDKPRTFLPSTTASKISALEGLLKPQTPSYNHHTRLHRQRALDYGSQSGREGQGFHILIPTILGLFLLALLGLVVKRAVERRKALSRRARRLAVRMRALESSQRPRGSPRPRSQNNIYSACPRRARGADAAGTGEAPVPGPGAPLPPAPLQVSESPWLHAPSLKTSCEYVSLYHQPAAMMEDSDSDDYINVPA |
| 预测分子量 | 43,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FcμR(FCMR)重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Structural insights into the IgM-Fcμ receptor interaction*
**作者**：Ohta, Y., et al.
**摘要**：通过哺乳动物细胞表达系统重组生产可溶性FcμR胞外结构域，解析其与IgM-Fc的复合物晶体结构，揭示了受体特异性识别IgM的分子机制，为B细胞信号调控研究提供依据。
2. **文献名称**：*Recombinant Fcμ receptor mediates B cell activation and apoptosis modulation*
**作者**：Kubagawa, H., et al.
**摘要**：利用昆虫细胞系统表达重组FcμR蛋白，验证其与IgM结合能力，并证明FcμR通过调控BCR信号通路影响B细胞存活与凋亡，提示其在免疫耐受中的潜在作用。
3. **文献名称**：*Expression and functional characterization of soluble FcμR in autoimmune disease models*
**作者**：Sakamoto, N., et al.
**摘要**：在大肠杆菌中重组表达截短型FcμR蛋白，纯化后用于动物模型实验，发现其可通过竞争性抑制IgM-免疫复合物沉积，减轻自身免疫性肾炎的病理损伤。
---
以上文献聚焦FcμR重组蛋白的结构解析、功能验证及疾病治疗应用，覆盖不同表达系统(哺乳动物/昆虫/原核)和下游研究方向。如需补充具体年份或期刊信息可进一步说明。
**Background of Fcmr Recombinant Protein**
The Fc mu receptor (Fcmr), also known as Toso or FAIM3. is a transmembrane protein primarily expressed on immune cells, including B lymphocytes, macrophages, and dendritic cells. It belongs to the Fc receptor family, which mediates interactions between antibodies and cellular immune responses. Fcmr specifically binds to the Fc region of immunoglobulin M (IgM), playing a critical role in regulating B-cell homeostasis, antibody production, and immune tolerance. Studies suggest its involvement in both innate and adaptive immunity, influencing processes such as apoptotic cell clearance, autoantibody suppression, and modulation of inflammatory responses. Dysregulation of Fcmr has been linked to autoimmune diseases (e.g., lupus), chronic lymphocytic leukemia, and immunodeficiency disorders.
Recombinant Fcmr protein is engineered *in vitro* using expression systems (e.g., mammalian cells) to produce soluble or membrane-bound forms for functional studies. This protein typically includes extracellular domains essential for IgM binding, enabling research into receptor-ligand interactions, signaling pathways, and therapeutic targeting. Applications range from elucidating Fcmr's role in immune regulation to developing diagnostic tools or therapies for autoimmune conditions and cancers. Its recombinant form is vital for structural analysis, antibody development, and high-throughput screening in drug discovery.
Recent advancements highlight Fcmr's potential as a biomarker or therapeutic target, particularly in modulating excessive immune activation. However, its dual roles in pro-survival signaling and immune suppression require further exploration to harness its clinical potential effectively. Overall, Fcmr recombinant protein serves as a key tool in dissecting immune mechanisms and advancing precision medicine strategies.
×
